首页> 美国卫生研究院文献>Journal of Applied Clinical Medical Physics >Dosimetric verification of inverse planned step and shoot multileaf collimator fields from a commercial treatment planning system
【2h】

Dosimetric verification of inverse planned step and shoot multileaf collimator fields from a commercial treatment planning system

机译:从商业处理计划系统进行反向计划步骤和多叶准直仪场的剂量学验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An inverse treatment planning (ITP) module on a commercial treatment planning system (TPS) (Helax AB, Uppsala, Sweden) is being used for an in‐house clinical trial for treatment of nasopharyngeal cancer with contralateral parotid sparing. Intensity modulated radiation therapy (IMRT) fields are delivered by step and shoot multileaf collimator (MLC) with a DMLC enabled Varian 2300 CD (Varian Associates, Palo Alto, CA). A series of testing procedures have been devised to quantify the modeling and delivery accuracy of routine clinical inverse planned IMRT using Helax TMS and the Varian step and shoot MLC delivery option. Testing was done on specific aspects of the TPS modeling germane to DMLC. Measured relative dose factors (head scatter plus phantom scatter) for small MLC fields, normalized to a 10 × 10cm2 non‐MLC field, were found to differ by 2–3% from the TPS values for the smallest of the fields tested. Relative distributions for small off axis fields were found to be in good agreement. A process for the routine clinical verification of IMRT fields has been implemented. Each IMRT field in an inverse plan is imported into a flat water tank plan and a “beam's eye view” (BEV) dose distribution is generated. This is compared to the corresponding measured BEV dose distribution. The IMRT verification process has also been performed using an anthropomorphic phantom. Large clinical fields (i.e., greater than 14.5 cm in the leaf direction) caused difficulties due to a vendor specific machine restriction, and several techniques for dealing with these were examined. These techniques were (i) the use of static stepping of closed junctions, (ii) the use of two separate IMRT fields for a given gantry angle, and (iii) restricting the overall maximum field size used. The overall process has allowed implementation of an in‐house protocol for IMRT use on an initial clinical site. Results of the verification measurements for the first ten patients treated at this center reveal an average maximum dose per IMRT field delivered of 71.0 cGy, with a mean local deviation from the planned dose of – 1.2 cGy, and a standard deviation of 2.4 cGy.PACS number(s): 87.53.Dq, 87.53.Tf
机译:商业治疗计划系统(TPS)上的反向治疗计划(ITP)模块(Helax AB,乌普萨拉,瑞典)正用于内部临床试验,以对侧腮腺保留治疗鼻咽癌。使用具有DMLC功能的Varian 2300 CD(加利福尼亚州帕洛阿尔托市的Varian Associates),分步和发射多叶准直仪(MLC)传送强度调制放射治疗(IMRT)场。已经设计了一系列测试程序,以量化使用Helax TMS和Varian step and Shoot MLC交付选项的常规临床逆计划IMRT的建模和交付准确性。在与DMLC紧密相关的TPS建模的特定方面进行了测试。发现小型MLC场的相对剂量因子(头部散射+幻像散射)已标准化为10×10cm 2 非MLC场,与MPS的TPS值相差2-3%。最小的测试领域。发现较小的离轴场的相对分布非常一致。已经实施了IMRT领域常规临床验证的过程。反向计划中的每个IMRT字段都将输入到平面水箱计划中,并生成“光束的视线”(BEV)剂量分布。将其与相应的测得的BEV剂量分布进行比较。 IMRT验证过程也已经使用拟人模型进行了。由于卖方特定的机器限制,较大的临床视野(即沿叶子方向大于14.5厘米)造成了困难,并研究了几种处理这些技术的方法。这些技术是(i)使用闭合结的静态步进,(ii)对于给定的龙门角度使用两个单独的IMRT场,以及(iii)限制使用的整体最大场尺寸。整个过程已允许在初始临床站点上实施IMRT内部协议。在该中心接受治疗的前十名患者的验证测量结果显示,每个IMRT视野平均平均最大剂量为71.0 cGy,与计划剂量的平均局部偏差为– 1.2 cGy,标准偏差为2.4 cGy.PACS号码:87.53.Dq,87.53.Tf

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号